GeoPharma (GORX) Receives Receives FDA Approval for Carprofen
More News related to GORX
- Trading Radar for 11/24: Heinz (HNZ), Dollar Tree (DLTR), Eaton Vance (EV), Hormel Foods (HRL), J. Crew (JCG) Report
- UPDATING and REPLACING -- GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Conference Call
- GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Conference Call
- GeoPharma (GORX) Reports a Q1 Loss
- GeoPharma (GORX) Announces Strategic Restructuring Plan
More News related to FDA
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
GeoPharma, Inc. (Nasdaq: GORX) received approval from the FDA to begin producing Carprofen.
Commonly marketed by Pfizer as Rimadyl, Carprofen is a non-steroidal anti-inflammatory drug that is used by veterinarians for the relief of pain and inflammation associated with osteoarthritis in dogs.
Related Categories
FDAStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
